Edition:
United States

PhaseRx Inc (PZRX.OQ)

PZRX.OQ on NASDAQ Stock Exchange Capital Market

0.49USD
15 Dec 2017
Change (% chg)

$0.12 (+33.53%)
Prev Close
$0.37
Open
$0.38
Day's High
$0.58
Day's Low
$0.36
Volume
782,909
Avg. Vol
173,767
52-wk High
$1.95
52-wk Low
$0.36

Latest Key Developments (Source: Significant Developments)

PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
Wednesday, 13 Dec 2017 07:05am EST 

Dec 13 (Reuters) - PhaseRx Inc ::PHASERX RECEIVES DECISION FROM THE NASDAQ HEARINGS PANEL FOR CONTINUED LISTING OF SHARES.PHASERX INC - BEEN GRANTED REQUEST FOR CONTINUED LISTING ON NASDAQ CAPITAL MARKET UNTIL JANUARY 31, 2018.  Full Article

Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding
Monday, 11 Dec 2017 07:05am EST 

Dec 11 (Reuters) - Phaserx Inc ::PHASERX COMMENCES VOLUNTARY CHAPTER 11 BANKRUPTCY PROTECTION PROCEEDING.PHASERX - WORKING WITH COWEN AND COMPANY TO REVIEW ALTERNATIVES.PHASERX - ALTERNATIVES MAY INCLUDE COLLABORATION WITH 1/MORE PARTIES OR LICENSING, SALE/DIVESTITURE OF SOME, OR ALL, OF CO'S PROPRIETARY TECHNOLOGIES​.  Full Article

PhaseRx reports Q3 loss per share $0.23
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - PhaseRx Inc :PhaseRx reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.23.PhaseRx Inc - ‍As of September 30, 2017, company had cash and cash equivalents of $5.3 million​.  Full Article

Phaserx gets delisting notice from NASDAQ
Thursday, 26 Oct 2017 06:30pm EDT 

Oct 26 (Reuters) - Phaserx Inc ::Says receipt of delisting notice from NASDAQ informing trading in co's stock will be suspended from NASDAQ at opening of business on Nov 1​.  Full Article

Phaserx announces corporate restructuring and review of strategic alternatives
Friday, 13 Oct 2017 08:30am EDT 

Oct 13 (Reuters) - PhaseRx Inc :PhaseRx announces corporate restructuring and review of strategic alternatives.PhaseRx inc - ‍Reorganization includes a reduction in PhaseRx's workforce by 10 employees​.PhaseRx Inc - ‍Board of directors has also begun a review of strategic alternatives, including but not limited to a potential merger transaction​.PhaseRx Inc - ‍As of June 30, 2017, PhaseRx had cash and equivalents of $8.4 million and a total of 20 employees​.PhaseRx Inc - ‍ Board of directors has made a determination to delay development of its lead product candidate PRX-OTC​.  Full Article

PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL
Wednesday, 20 Sep 2017 02:08pm EDT 

Sept 20 (Reuters) - PhaseRx Inc ::PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the treatment of Argininosuccinate Lyase Deficiency.  Full Article

Phaserx reports Q2 loss per share $0.30
Thursday, 10 Aug 2017 08:30am EDT 

Aug 10 (Reuters) - Phaserx Inc :Phaserx reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.30.  Full Article

PhaseRx files for stock and warrants offering of up to $15 mln
Wednesday, 21 Jun 2017 04:22pm EDT 

June 21 (Reuters) - PhaseRx Inc -:PhaseRx Inc files for stock and warrants offering of up to $15 million - sec filing.  Full Article

Phaserx reports Q1 loss per share $0.35
Friday, 12 May 2017 08:30am EDT 

May 12 (Reuters) - Phaserx Inc ::Phaserx reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.35.Phaserx Inc - as of March 31, 2017, company had cash, cash equivalents, and marketable securities of $11.9 million.Phaserx - revising timeline for submission of IND for PRX-OTC to 2018, expect to generate clinical efficacy data in affected patients in H2 of 2018.  Full Article

PhaseRx reports Q4 loss per share of $0.30
Monday, 27 Mar 2017 08:30am EDT 

Phaserx Inc : PhaseRx reports fourth quarter and full year 2016 financial results and provides corporate update . Q4 loss per share $0.30 . As of December 31, 2016, company had cash, cash equivalents, and marketable securities of $15.5 million . Believes it has sufficient cash to fund its operations for at least next 12 months .In 2017, anticipate completing GLP toxicology and GMP manufacturing activities and submitting an ind for PRX-OTC in Q4.  Full Article

BRIEF-PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares

* PHASERX RECEIVES DECISION FROM THE NASDAQ HEARINGS PANEL FOR CONTINUED LISTING OF SHARES